These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27641983)

  • 1. Second generation direct-acting antivirals - Do we expect major improvements?
    Feld JJ; Foster GR
    J Hepatol; 2016 Oct; 65(1 Suppl):S130-S142. PubMed ID: 27641983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    Moradpour D; Grakoui A; Manns MP
    J Hepatol; 2016 Oct; 65(1 Suppl):S143-S155. PubMed ID: 27641984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What does the pharmacological future of treating chronic hepatitis C look like?
    Heil EL; Hynicka LM; Kottilil S; Tang L
    Expert Rev Clin Pharmacol; 2015; 8(5):605-22. PubMed ID: 26289223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
    Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
    Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of strategy-based approach to treatment of genotype 1 chronic hepatitis C.
    Zhao YJ; Khoo AL; Lin L; Teng M; Koh CJ; Lim SG; Lim BP; Dan YY
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1628-37. PubMed ID: 26990023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
    Asselah T; Bourlière M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.
    Sinakos E; Kountouras D; Koskinas J; Zachou K; Karatapanis S; Triantos C; Vassiliadis T; Goulis I; Kourakli A; Vlachaki E; Toli B; Tampaki M; Arvaniti P; Tsiaoussis G; Bellou A; Kattamis A; Maragkos K; Petropoulou F; Dalekos GN; Akriviadis E; Papatheodoridis GV
    Br J Haematol; 2017 Jul; 178(1):130-136. PubMed ID: 28439915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.
    Ji D; Chen GF; Wang C; Wang YD; Shao Q; Li B; Zhao J; You SL; Hu JH; Liu JL; Niu XX; Chen J; Lu L; Wu V; Lau G
    Hepatol Int; 2016 Sep; 10(5):789-98. PubMed ID: 27443347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and Evolving Treatments of Genotype 1 Hepatitis C Virus.
    Alqahtani S; Sulkowski M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):825-43. PubMed ID: 26600222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C: How Good Are Real-Life Data and Do Generics Work.
    Tran AN; Lim JK
    Gastroenterol Clin North Am; 2020 Jun; 49(2):279-299. PubMed ID: 32389363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
    Izumi N; Takehara T; Chayama K; Yatsuhashi H; Takaguchi K; Ide T; Kurosaki M; Ueno Y; Toyoda H; Kakizaki S; Tanaka Y; Kawakami Y; Enomoto H; Ikeda F; Jiang D; De-Oertel S; McNabb BL; Camus G; Stamm LM; Brainard DM; McHutchison JG; Mochida S; Mizokami M
    Hepatol Int; 2018 Jul; 12(4):356-367. PubMed ID: 30030720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatitis C: a systematic review.
    Kohli A; Shaffer A; Sherman A; Kottilil S
    JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV targeting of patients with cirrhosis.
    Ferenci P; Kozbial K; Mandorfer M; Hofer H
    J Hepatol; 2015 Oct; 63(4):1015-22. PubMed ID: 26100497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.